Dated September 17, CHMP Recommends EU Label Expansion For Novartis' Cosentyx In Polymyalgia Rheumatica After Inadequate Glucocorticoid Response Or Relapse During Taper
https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cosentyx-vr-0000326984_en.pdf
Share
Why It Matters
Novartis got approval to use Cosentyx for a new disease in Europe. This means the medicine can help more patients, which could boost sales.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.